FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors

DRREDDY

5,003.15
-18.85 (-0.38%)
Updated 03:29 23/10 IST

DRREDDY Buy or Sell - FrontPage Forums

0 Users have submitted 0 trade ideas of Rs. 0 for DRREDDY
Disclaimer
0% Bullish
0% Bearish

DRREDDY Buy or Sell - Brokerage Reports

No. of reports in last year
19
No. of analysts
8
Average Consensus Forecast
4283.47
Consensus Potential
-24.79%
See DRREDDY Share Price Targets >>

DRREDDY Ratings

Long term DRREDDY rating by FrontPage users
4.5/5 (11 Ratings)
Find answers to all your questions on live DRREDDY message board: Is DRREDDY buy or sell? Should I buy DRREDDY shares? Why are DRREDDY shares falling? Should I invest in DRREDDY stock?

  1. Home
  2. DRREDDY Forum

DRREDDY Share Price Discussion

N
Reputation: 7,204 • Today 2:53 AM
Coronavirus vaccine update: Dr Reddy's to test Sputnik V on 100 volunteers in phase 2
Upon regulatory approval in India, RDIF will supply 100 million doses of Sputnik V to Dr Reddy's.
Moneycontrol
Like
Reply
T
Reputation: 25,082 • Today 2:44 AM
Like
Reply
Like
Reply (1)
See all replies
Akash @akash-HJbZksWOD
Today 2:16 AM

How long one should hold it
N
Reputation: 7,204 • Today 1:18 AM
ICICI Bank shuts down operations in Sri Lanka
The Monetary Board of the Central Bank of Sri Lanka, having considered the request made by ICICI Bank, has granted approval to close down business operation of the bank in Sri Lanka and cancel the licence issued to it, ICICI Bank said in a regulatory filing.
Moneycontrol
Like
Reply
N
Reputation: 7,204 • Today 1:13 AM
Unsustainable debt symptom of fundamental issues in company's business model: SBI executive
Arijit Basu, Managing Director of Commercial Clients Groups at State Bank of India (SBI), also said the Insolvency and Bankruptcy Code (IBC) has provided equal opportunity to corporate sector and banks.
Moneycontrol
Like
Reply

✅ POSITIONAL✅
ABOVE 350
TARGETS 450
SL 250
For more calls WhatsApp 7897404773
Like
Reply
Like
Reply

TOWER TALK 24/10/2020

SBI Card’s Q2FY21 profit fell to Rs.206 crore from Rs.381 crore in Q2FY20. Its Q2 NPAs are much higher than the 4.3% reported given the Supreme Court restriction on reporting Covid-19 related defaults. SELL.

Umang Dairies, a part of the JK Group, posted ov...
Read more...
1
Reply
N
Reputation: 7,204 • Yesterday 4:28 AM
Tata Motors crosses 40 lakh cumulative production milestone
The company has been focussing not only on the safety aspect of its vehicles but has also been leading the electric vehicle space in the country, Tata Motors President Passenger Vehicles Business Unit (PVBU) Shailesh Chandra said.
Moneycontrol
Like
Reply
1
Reply

*MONEYTIMES TALK*
SBI Card’s Q2FY21 profit fell to Rs.206 crore from Rs.381 crore in Q2FY20. Its Q2 NPAs are much higher than the 4.3% reported given the Supreme Court restriction on reporting Covid-19 related defaults. SELL.
Umang Dairies, a part of the JK Group, posted over 80%...
Read more...
1
Reply
Like
Reply
Eagle 4 AIM
TIP OF THE DAY: Don’t just trust any breakout o...
Like
Reply

SRF - 1527404

The stock gave Fibonacci 23.6% levels after a retracement to 38.2% in 2 hours TF.
BUY ABOVE 4445
Like
Reply

IDX:NIFTY 50 - chart - 1527401

we are still in the range of 12000 and 11800
a clear break of either these levels can give good move for coming months
however a sudden break of this levels are not expected it could be consolidating for coming weeks too
so trade safe !protect capital!

stay tuned for...
Read more...
1
Reply

#TATASTEEL it just made a good triangle pattern. Also just touched a good resistance level. Could give breakdown and give a profitable target for short sellers. Also may consolidate first and then fall. 😇😇😇
TATASTEEL - chart - 1527393
Like
Reply

BIGBLOC - chart - 1527391
#BIGBLOC MEDIUM TERM BUY MODE TGT 92/128 SL 63 ( WEEKLY CLBS)
Like
Reply

REDINGTON - chart - 1527390
#REDINGTON MEDIUM TERM BUY MODE TGT 144/169 SL 120 ( WEEKLY CLBS )
Like
Reply
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 50,000 Indian traders and discuss trades, strategies, news & views on any stock.
  • DRREDDY - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization46,050.89
    Enterprise Value46,829.69
    Price to Earnings61.08
    Price to Book Value3.63
    Return on Capital Employed0.05
    Return on Equity0.05
    Face Value5
    Dividend Yield0.01
  • DRREDDY - Brokerage Reports

    keyboard_arrow_down
    DateBrokerageCallTarget
    5-Oct-20Prabhudas LilladherAccumulate5,648
    1-Oct-20Axis DirectBuy6,200
    24-Sep-20Prabhudas LilladherAccumulate5,648
    18-Sep-20ICICIdirect.comBuy5,710
    18-Sep-20Nirmal BangBuy5,656
    DRREDDY Brokerage Price Target
  • DRREDDY Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Oct 235051509149965018.25
    Oct 225036.75044.748315022
    Oct 215096.555096.554906.555046.75
    Oct 205056.9551105030.955071.15
    Oct 19521152155042.055058.15
  • DRREDDY Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹5,111.99
    30 Day Moving Average₹4,996.46
    50 Day Moving Average₹4,769.54
    100 Day Moving Average₹4,442
    200 Day Moving Average₹3,887.06
  • DRREDDY - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue9,3599,719.8-0.04
    Operating Profit1,3301,745.6-0.24
    Profit Before Tax6971,544.5-0.55
    Net Income5661,384.1-0.59
  • DRREDDY - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-19Mar-18 % Change
    Shareholder's Funds12,68411,8070.07
    Total Liabilities3,5645,545-0.36
    Total Assets16,24817,353-0.06
  • DRREDDY - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity1,5381,015.90.51
    Cash from Investing Activity-1,1801,430.5-1.82
    Cash from Financing Activity-304-2,581.8-0.88
    Net Cash Flow54-135.4-1.4
  • DRREDDY - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets0.030.08
    Return on Equity0.050.12
    Return on Capital Employed0.050.11
  • DRREDDY - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue-0.07
    3 Year CAGR Growth in Operating Profit-0.44
    3 Year CAGR Growth in EBIDTA-0.41
    3 Year CAGR Growth in Net Income-0.66
    3 Yr CAGR Growth - Diluted EPS-0.65
  • DRREDDY - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue0.12
    5 Year CAGR Growth in Operating Profit-0.33
    5 Year CAGR Growth in EBIDTA-0.28
    5 Year CAGR Growth in Net Income-0.55
    3 Yr CAGR Growth - Diluted EPS-0.54
  • DRREDDY - Recent News

    keyboard_arrow_down
    NewsBot
    Today 2:53 AM
    Coronavirus vaccine update: Dr Reddy's to test Sputnik V on 100 volunteers in phase 2
    Moneycontrol
    NewsBot
    Oct 22 6:58 AM
    Dr Reddy's Labs shares trade lower as data breach forces the company to shut plants
    Moneycontrol
    NewsBot
    Oct 22 5:53 AM
    Days after Russian COVID-19 vaccine trial approval, data breach forces Dr Reddy's to shut plants
    Moneycontrol
    NewsBot
    Oct 22 4:58 AM
    Dr Reddy's Lab shares fall 4% after firm shuts plants on reports of data breach
    Moneycontrol
    NewsBot
    Oct 22 4:53 AM
    Days after Russian COVID-19 vaccine trial approval, data breach forces Dr Reddy's to shut plants: Reports
    Moneycontrol
    NewsBot
    Oct 22 4:28 AM
    Dr. Reddy's Laboratories shuts plants after data breach: Report
    Moneycontrol
    NewsBot
    Oct 20 9:58 AM
    Dr Reddy's launches generic product in US to treat gastroesophageal reflux disease
    Moneycontrol
    NewsBot
    Oct 18 6:03 AM
    Russia's COVID-19 vaccine Sputnik V makes headway in India
    Moneycontrol
    NewsBot
    Oct 6 6:33 AM
    Accumulate Dr. Reddy's Laboratories; target of Rs 5648: Prabhudas Lilladher
    Moneycontrol
    NewsBot
    Oct 6 4:03 AM
    Russian COVID-19 vaccine update: Dr Reddy's told to submit revised application for phase 2, 3 clinical trials of Sputnik V
    Moneycontrol
  • DRREDDY - Related Communities

    keyboard_arrow_down
    Sun Pharmaceutical Industries Ltd. NS...
    Cipla Ltd. NSE: CIPLA | BSE: 500087 |...
    Aurobindo Pharma Ltd. NSE: AUROPHARMA...
    Biocon Ltd. NSE: BIOCON | BSE: 532523...
    Lupin Ltd. NSE: LUPIN | BSE: 500257 |...
    Glenmark Pharmaceuticals Ltd. NSE: GL...
    Piramal Enterprises Ltd. NSE: PEL | B...
    Divi's Laboratories Ltd. NSE: DIVISLA...
    Apollo Hospitals Enterprise Ltd. NSE:...
    Cadila Healthcare Ltd. NSE: CADILAHC ...
  • DRREDDY - More Information

    keyboard_arrow_down

    Dr Reddy's Laboratories Ltd:
    Dr Reddy's Laboratories Limited has been acquiring a worldwide recognition in the pharmaceutical market for the last three decades. The company is running its operation through three core segments viz. Pharmaceutical Services and Active Ingredients (PSAI), Global Generics and Proprietary Products.
    Active pharmaceutical ingredients are manufactured and marketed by this PSAI segment. These are the essential ingredients for finished pharmaceutical products. In the basis of specific customer requirements, the company is providing active pharmaceutical ingredients and steroids. The Proprietary Product segment refers to the research and development procedures of the firm. Along with that, these segments deals with manufacturing and selling dermatological and neurological therapeutic issues.
    The company deals with several therapeutic issues such as respiratory, cardiovascular, respiratory, anti-diabetic, urology, gastrointestinal, nephrology, oncology and stomatology. The company has strong business-relation with Curis Inc. regarding the research, development and marketing of small molecules for precision oncology and precision oncology. Having its head office at Hyderabad in India, Dr Reddy's Laboratories Limited was founded in 1984.
    About Company Information:
    Soon after its establishment with an initial investment of Rs.25 lacs, the company started the manufacturing of Active Pharmaceutical Ingredients and Intermediates in a 60-tonne manufacturing plant near Hyderabad, India. The Bombay Stock Exchange enlisted the company in 1986. USDA approval for manufacturing Ibuprofen was given to the company for the first time in the year of 1987.
    For developing and expanding the market and production of Bulk Actives, the company acquired Benzex Laboratories Pvt Ltd in 1988. Norfloxacin and Ciprofloxacin were started to be exported by the company from 1990 mostly in Europe and East, just a year before commencing formulation exports to Russia in 1991. Dr Reddy's Research Foundation was inaugurated by the company in 1993.
    In 1995, the company had gone for a joint venture in Russia. Company's first ANDA was filled with United States Food and Drug Administration for manufacturing Ranitidine in 1997. India-based pharmaceutical company American Remedies Ltd was acquired by the firm in 1999.
    The company turned to be the third-largest pharmaceutical organization in India in 2000 when a merger took place between the company and Cheminor Drugs Ltd. Fluoxetine capsules were introduced by the company in 2001.
    The company commenced their debut acquisition in abroad when it acquired Meridian Healthcare and BMS Laboratories Limited at the UK in 2002. Ibuprofen was launched as the first generic under Dr Reddy's label at US market in 2003. Roche's API manufacturing business at Mexico was acquired by the company in 2005 just a year back of buying Germany's fourth-largest generic company Betapharm against an amount of Rs.480 million in 2006. Plant's first biosimilar MAb, for treating Non-Hodgkins Lymphoma was introduced by Dr Reddy's Laboratories Limited in 2007.
    A cent per cent subsidiary of the company with a 'Special Economic Zone' facility namely, Dr Reddys Pharma SEZ Ltd was established during 2009-10. At the same period, an amalgamation with Perlecan Pharma Pvt Ltd took place. The oral penicillin manufacturing plant of Glaxo Smith Kline at Tennessee in the USA was acquired by the company during 2010-11.
    US Federal Trade Commission issued an order of consent on November 2014, allowing the acquisition of Novartis Consumer Health Inc.'s Habitrol brand by Dr Reddy's Laboratories Limited which was finally announced officially by Dr Reddy's Laboratories in December 2014.
    A warning letter was issued from US Food and Drug Administration accusing Dr Reddys Laboratories Limited regarding the API manufacturing plants of the firm at Miryalaguda, Telangana and Andhra's Srikakulam along with the manufacturing facility of Oncology Formulation at Vishakhapatnam, Andhra Pradesh on November 2015. The company started to intervene in the market of Colombia with premium quality cancer medicines at affordable prices in October of 2016.
    The manufacturing, research, future development and commercialization of DFD-06, a topical steroid with enormous potential, had been out-licensed to Encore Dermatology Inc. by Promius Pharma, LLC, a cent per cent owned subsidiary of Dr Reddys Laboratories Ltd in the August of 2017.
    How Dr Reddy's Laboratories Ltd, is categorised as a Pharmaceuticals and Healthcare Sector, and Pharmaceutical Industry :
    The Pharmaceutical Industry includes companies that derive their business by researching, discovering, developing, manufacturing, and marketing and distributing pharmaceutical medicines and drugs.
    Dr Reddy's Laboratories Ltd is categorized under the Pharmaceutical and Health care sector and Pharmaceutical Industry. Healthcare sectors consist of firms involved in the medical space. It is one of the multiple sectors that comprise a range of businesses, including ones that offer medical services directly, or to those that work to develop, create and market medical equipment and medicines. It also includes the other services that provide medical insurance and other related products, and many more.
    The stocks of health care companies mostly have mixed performance. It is due to the inherent challenges to the industry each year, regulatory uncertainties, fiscal policy concerns, and more.
    Dr Reddy's Laboratories Ltd, Competitors and Sector Peers:
    Abbott India Ltd. ABBIND
    Alembic Ltd. ALELTD
    Alembic Pharmaceuticals Ltd. ALEPHA
    Alkem Laboratories Ltd. ALKLAB
    Alpa Laboratories Ltd. ALPLAB
    Ambalal Sarabhai Enterprises Ltd. AMBSAR
    AstraZeneca Pharma India Ltd. ASTZEN
    Bafna Pharmaceuticals Ltd. BAFPHA
    Bajaj Healthcare Ltd. BAJHEA
    Biocon Ltd. BIOLTD
    Cian Healthcare Ltd.
    Cipla Ltd. CIPLTD
    Concord Drugs Ltd. CONDRU
    Dishman Pharmaceuticals & Chemicals Ltd.[Merged] DISPHA
    Divi's Laboratories Ltd. DIVIL
    Dr. Reddy's Laboratories Ltd. DR
    GlaxoSmithKline Pharmaceuticals Ltd. GLAPHA
    Glenmark Pharmaceuticals Ltd. GLEPHL
    IOL Chemicals and Pharmaceuticals Ltd. IOLCHE
    Lincoln Pharmaceuticals Ltd. LINPHA
    Lupin Ltd. LUPLTD
    Madhuveer Com 18 Network Ltd. TOHPHA
    Mahavir Advanced Remedies Ltd. INDAME
    Makers Laboratories Ltd. MAKLAB
    Natco Pharma Ltd. NATPHA
    Natural Capsules Ltd. NATCAP
    Ranbaxy Laboratories Ltd. RANLAB
    Sanofi India Ltd. AVEPHA
    Sharon Bio-Medicine Ltd. SHAPHA
    Sun Pharmaceutical Industries Ltd. SUN28
    Zenith Healthcare Ltd. ZENHEA
    Zyden Gentec Ltd. ZYDGEN
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.

PrivacyTerms
FrontPage © 2020